Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
about
Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines.Prevention of stent thrombosis: challenges and solutions.Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.Real-world incidence of patient-reported dyspnoea with ticagrelor
P2860
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dyspnea and reversibility of a ...... nogrel, cangrelor, and beyond.
@en
type
label
Dyspnea and reversibility of a ...... nogrel, cangrelor, and beyond.
@en
prefLabel
Dyspnea and reversibility of a ...... nogrel, cangrelor, and beyond.
@en
P2860
P356
P1433
P1476
Dyspnea and reversibility of a ...... nogrel, cangrelor, and beyond.
@en
P2093
Dirk Sibbing
Victor L Serebruany
P2860
P356
10.1159/000354876
P407
P577
2013-10-26T00:00:00Z